Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Pulmonx Co. (NASDAQ:LUNG) have received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $12.75.

A number of brokerages have weighed in on LUNG. Stifel Nicolaus reduced their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Citigroup restated a “neutral” rating and issued a $7.50 target price (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th.

Insider Activity

In other news, Director Glendon E. French III sold 20,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $6.63, for a total transaction of $132,600.00. Following the completion of the transaction, the director now owns 1,071,974 shares of the company’s stock, valued at approximately $7,107,187.62. This represents a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Geoffrey Beran Rose sold 4,376 shares of Pulmonx stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.18, for a total value of $27,043.68. Following the sale, the insider now directly owns 291,057 shares in the company, valued at approximately $1,798,732.26. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,199 shares of company stock valued at $208,859. 5.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC raised its stake in shares of Pulmonx by 141.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 109,105 shares of the company’s stock valued at $692,000 after buying an additional 63,945 shares in the last quarter. SG Americas Securities LLC acquired a new position in Pulmonx in the third quarter worth about $102,000. nVerses Capital LLC bought a new position in Pulmonx during the third quarter worth about $26,000. GSA Capital Partners LLP acquired a new stake in Pulmonx during the third quarter valued at approximately $537,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Pulmonx in the 3rd quarter valued at approximately $480,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Stock Up 6.6 %

LUNG opened at $6.15 on Thursday. The company has a market capitalization of $242.86 million, a PE ratio of -4.18 and a beta of 0.64. The business has a 50-day moving average of $6.34 and a 200-day moving average of $6.79. Pulmonx has a fifty-two week low of $5.46 and a fifty-two week high of $14.84. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.